Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Κύριοι συγγραφείς: | Aoki, Y, Wood, MJA |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
IOS Press
2021
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Oligonucleotide-based therapies for neuromuscular disease
ανά: Douglas, A, κ.ά.
Έκδοση: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
ανά: Tsoumpra, MK, κ.ά.
Έκδοση: (2019) -
Advances in oligonucleotide drug delivery
ανά: Roberts, TC, κ.ά.
Έκδοση: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
ανά: Ashok Verma
Έκδοση: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
ανά: Gait, M, κ.ά.
Έκδοση: (2018)